Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone Open-Label Extension in Schizophrenia
NCT01566162Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Apr 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of lurasidone in schizophrenia, sponsored by Sumitomo Pharma America. Primary endpoints: Treatment-emergent Adverse Events at 12 weeks, Positive and Negative Syndrome Scale Total Score at 12 weeks and 1 more. Started Apr 2012; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01566162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01566162.